NZ600267A - Combined oral preparation of theobromine and a decongestant for cough therapy - Google Patents

Combined oral preparation of theobromine and a decongestant for cough therapy

Info

Publication number
NZ600267A
NZ600267A NZ600267A NZ60026710A NZ600267A NZ 600267 A NZ600267 A NZ 600267A NZ 600267 A NZ600267 A NZ 600267A NZ 60026710 A NZ60026710 A NZ 60026710A NZ 600267 A NZ600267 A NZ 600267A
Authority
NZ
New Zealand
Prior art keywords
theobromine
decongestant
antihistamine
oral preparation
combined oral
Prior art date
Application number
NZ600267A
Inventor
John Brew
Robin Mark Bannister
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Priority claimed from PCT/GB2010/052085 external-priority patent/WO2011073646A1/en
Publication of NZ600267A publication Critical patent/NZ600267A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

ABSTRACT - 600267 The disclosure relates to an agent consisting of theobromine and an antihistamine as a combined preparation for use in a therapy of cough, wherein the agent is manufactured for administration by an oral route, wherein the antihistamine is selected from diphenhydramine, loratadine, desloratadine, alimemazine, dimenhydrinate, doxylamine, meclizine, quetiapine, fexofenadine, pheniramine, cetirizine, promethazine, clemastine, chlorpheniramine, dexchlorpheniramine, levocetirizine, hydroxyzine, alimemazine, acrivastine, cyproheptadine, astemizole, fexofenadine, loratadine, cetirizine, levocetirizine, brompheniramine, dextrobrompheniramine, promethazine, mizolastine, and triprolidine, and wherein the antihistamine, preferably chlorpheniramine, is to be administered in a dose of 0.1 to 30 mg/kg/day.
NZ600267A 2009-12-14 2010-12-14 Combined oral preparation of theobromine and a decongestant for cough therapy NZ600267A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0921803.3A GB0921803D0 (en) 2009-12-14 2009-12-14 Drug composition and its use in therapy
PCT/GB2010/052085 WO2011073646A1 (en) 2009-12-14 2010-12-14 Combination of theobromine with a decongestant and its use for the treatment of cough

Publications (1)

Publication Number Publication Date
NZ600267A true NZ600267A (en) 2013-07-26

Family

ID=41667043

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ600267A NZ600267A (en) 2009-12-14 2010-12-14 Combined oral preparation of theobromine and a decongestant for cough therapy

Country Status (17)

Country Link
EP (1) EP2512472A1 (en)
JP (2) JP2013513652A (en)
CN (1) CN102802625A (en)
AU (1) AU2010332495C1 (en)
BR (1) BR112012014159A8 (en)
CA (1) CA2784215A1 (en)
CO (1) CO6541638A2 (en)
GB (1) GB0921803D0 (en)
IL (1) IL220384A0 (en)
MX (1) MX2012006624A (en)
NZ (1) NZ600267A (en)
PE (1) PE20121538A1 (en)
RU (1) RU2012129675A (en)
SG (2) SG10201408374WA (en)
UA (1) UA105827C2 (en)
WO (1) WO2011073647A1 (en)
ZA (1) ZA201204294B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910375D0 (en) 2009-06-16 2009-07-29 Biocopea Ltd Drug composition and its use in therapy
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
US9314465B2 (en) 2009-06-16 2016-04-19 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9308211B2 (en) 2009-06-16 2016-04-12 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
CN103263533B (en) * 2013-05-31 2014-11-05 杨宏伟 Theobromine composition for treating cough and application and preparation thereof
CN104188998A (en) * 2014-09-18 2014-12-10 中山大学 Naringin and fexofenadine hydrochloride drug composition and preparation thereof
CN104224819B (en) * 2014-09-18 2016-08-17 中山大学 A kind of naringin and levo-cetirizine hydrochloride pharmaceutical composition and preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE59550T1 (en) * 1986-04-17 1991-01-15 Alza Corp CHLORPHENIRAMINE THERAPY.
HUP9700654A2 (en) 1997-03-26 1999-09-28 Dezső Korbonits Antitussive compositions containing theobromine
JPH10316568A (en) * 1997-05-13 1998-12-02 Taisho Pharmaceut Co Ltd Pharmaceutical composition
JP2003012514A (en) * 2001-07-02 2003-01-15 Taisho Pharmaceut Co Ltd Medicament composition
JP2003128549A (en) * 2001-08-15 2003-05-08 Rohto Pharmaceut Co Ltd Composition applicable to mucous membrane
US20080003280A1 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
RU2009141592A (en) * 2007-04-11 2011-05-20 Алькон Рисерч, Лтд. (Us) USE OF TNFα INHIBITOR IN COMBINATION WITH ANTIHISTAMINE TREATMENT FOR TREATMENT OF ALLERGIC RHINITIS AND ALLERGIC CONJUNCTIVITIS

Also Published As

Publication number Publication date
AU2010332495C1 (en) 2016-02-11
AU2010332495B2 (en) 2015-01-22
BR112012014159A2 (en) 2017-08-29
PE20121538A1 (en) 2012-12-21
WO2011073647A1 (en) 2011-06-23
JP2013513652A (en) 2013-04-22
JP6078605B2 (en) 2017-02-08
MX2012006624A (en) 2012-10-05
CA2784215A1 (en) 2011-06-23
RU2012129675A (en) 2014-01-27
EP2512472A1 (en) 2012-10-24
SG181603A1 (en) 2012-07-30
SG10201408374WA (en) 2015-01-29
CN102802625A (en) 2012-11-28
CO6541638A2 (en) 2012-10-16
JP2016040280A (en) 2016-03-24
GB0921803D0 (en) 2010-01-27
ZA201204294B (en) 2013-02-27
AU2010332495A1 (en) 2012-06-21
IL220384A0 (en) 2012-08-30
BR112012014159A8 (en) 2017-12-26
UA105827C2 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
NZ600267A (en) Combined oral preparation of theobromine and a decongestant for cough therapy
ZA202303227B (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
PL3599237T3 (en) Pharmaceutical composition of the glucosylceramide synthase inhibitor eliglustat for the treatment of gaucher's disease comprising adjusting the individual therapeutical dose to the p450 metabolism of the patient
US8097625B2 (en) Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
NZ702485A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
JP2013513652A5 (en)
TW200602022A (en) Use of PDE III inhibitor for the reduction of heart size in mammals suffering from heart failure
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
IL212586A (en) 3-(1,3-benzoxazol-5-yl)-pyrazolo[3,4-d]pyrimidin-4-amine derivative, a pharmaceutical composition and the use of the derivative for the manufacture of a medicament
UA104136C2 (en) Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
EP1587925A4 (en) A process for delivering sirna to cardiac muscle tissue
NZ596125A (en) Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
NZ600243A (en) Combination of theobromine with a decongestant and its use for the treatment of cough
NZ595798A (en) Ectoparasiticidal methods and formulations
HK1103280A1 (en) Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1765989A4 (en) Therapeutic delivery of adenosine into a tissue
Roberge Antiemetic-related dystonic reaction unmasked by removal of a scopolamine transdermal patch
WO2011156822A3 (en) Pharmaceutical compositions
UA93755C2 (en) Agent exhibiting nootropic, anticholesterosis activity, recovering and stimulating neuromuscular transmission
Vardar Hypomania in a patient receiving ECT: case report
MX2009006735A (en) Gelatin capsules comprising an acid.
Lim JongHwan et al. Plasma and tissue depletion of florfenicol in olive flounder (Paralichthys olivaceus) after oral administration.
肖培根 Preface for the First Issue of Chinese Herbal Medicines

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE UNKNOWN(124) HAS BEEN CORRECTED TO 25/05/2012

Effective date: 20130718

ERR Error or correction

Free format text: THE UNKNOWN(124) HAS BEEN CORRECTED TO 28/05/2012

Effective date: 20130911

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 DEC 2015 BY OLCOTT

Effective date: 20141012

ASS Change of ownership

Owner name: INFIRST HEALTHCARE LIMITED, GB

Effective date: 20141106

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 DEC 2016 BY OLCOTT

Effective date: 20151128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 DEC 2017 BY OLCOTT INTERANTIONAL

Effective date: 20161205

LAPS Patent lapsed